254 related articles for article (PubMed ID: 30582389)
21. Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rat model of arterial injury.
Wu B; Mottola G; Chatterjee A; Lance KD; Chen M; Siguenza IO; Desai TA; Conte MS
J Vasc Surg; 2017 Jan; 65(1):207-217.e3. PubMed ID: 27034112
[TBL] [Abstract][Full Text] [Related]
22. Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis.
Salazar J; Pirela D; Nava M; Castro A; Angarita L; Parra H; Durán-Agüero S; Rojas-Gómez DM; Galbán N; Añez R; Chacín M; Diaz A; Villasmil N; De Sanctis JB; Bermúdez V
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328553
[TBL] [Abstract][Full Text] [Related]
23. Resolution of inflammation in oral diseases.
Eltay EG; Van Dyke T
Pharmacol Ther; 2023 Jul; 247():108453. PubMed ID: 37244405
[TBL] [Abstract][Full Text] [Related]
24. Regulation of T-Cell Immune Responses by Pro-Resolving Lipid Mediators.
Perez-Hernandez J; Chiurchiù V; Perruche S; You S
Front Immunol; 2021; 12():768133. PubMed ID: 34868025
[TBL] [Abstract][Full Text] [Related]
25. Formation of lipoxins and resolvins in human leukocytes.
Kahnt AS; Schebb NH; Steinhilber D
Prostaglandins Other Lipid Mediat; 2023 Jun; 166():106726. PubMed ID: 36878381
[TBL] [Abstract][Full Text] [Related]
26. Role of specialized pro-resolving lipid mediators and their receptors in virus infection: a promising therapeutic strategy for SARS-CoV-2 cytokine storm.
Lee CH
Arch Pharm Res; 2021 Jan; 44(1):84-98. PubMed ID: 33398691
[TBL] [Abstract][Full Text] [Related]
27. Pro-inflammatory and pro-resolving mechanisms in the immunopathology of arteriovenous fistula maturation.
Satish M; Gunasekar P; Agrawal DK
Expert Rev Cardiovasc Ther; 2019 May; 17(5):369-376. PubMed ID: 31056981
[No Abstract] [Full Text] [Related]
28. Resolvins: Emerging Players in Autoimmune and Inflammatory Diseases.
Abdolmaleki F; Kovanen PT; Mardani R; Gheibi-Hayat SM; Bo S; Sahebkar A
Clin Rev Allergy Immunol; 2020 Feb; 58(1):82-91. PubMed ID: 31267470
[TBL] [Abstract][Full Text] [Related]
29. Pro-resolving lipid mediators: Agents of anti-ageing?
Doyle R; Sadlier DM; Godson C
Semin Immunol; 2018 Dec; 40():36-48. PubMed ID: 30293857
[TBL] [Abstract][Full Text] [Related]
30. Targeting Angiogenesis via Resolution of Inflammation.
Kelly AG; Panigrahy D
Cold Spring Harb Perspect Med; 2023 Mar; 13(3):. PubMed ID: 35817542
[TBL] [Abstract][Full Text] [Related]
31. Resolution of inflammation is altered in Alzheimer's disease.
Wang X; Zhu M; Hjorth E; Cortés-Toro V; Eyjolfsdottir H; Graff C; Nennesmo I; Palmblad J; Eriksdotter M; Sambamurti K; Fitzgerald JM; Serhan CN; Granholm AC; Schultzberg M
Alzheimers Dement; 2015 Jan; 11(1):40-50.e1-2. PubMed ID: 24530025
[TBL] [Abstract][Full Text] [Related]
32. Specialized Pro-Resolving Mediators and the Lymphatic System.
Kraft JD; Blomgran R; Lundgaard I; Quiding-Järbrink M; Bromberg JS; Börgeson E
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803130
[TBL] [Abstract][Full Text] [Related]
33. Specialized Pro-Resolving Mediators as Resolution Pharmacology for the Control of Pain and Itch.
Ji RR
Annu Rev Pharmacol Toxicol; 2023 Jan; 63():273-293. PubMed ID: 36100219
[TBL] [Abstract][Full Text] [Related]
34. Pro-resolution therapeutics for cardiovascular diseases.
Heinz J; Marinello M; Fredman G
Prostaglandins Other Lipid Mediat; 2017 Sep; 132():12-16. PubMed ID: 28450270
[TBL] [Abstract][Full Text] [Related]
35. The resolution of inflammation through omega-3 fatty acids in atherosclerosis, intimal hyperplasia, and vascular calcification.
Carracedo M; Artiach G; Arnardottir H; Bäck M
Semin Immunopathol; 2019 Nov; 41(6):757-766. PubMed ID: 31696250
[TBL] [Abstract][Full Text] [Related]
36. Role of specialized pro-resolving lipid mediators in pulmonary inflammation diseases: mechanisms and development.
Yang A; Wu Y; Yu G; Wang H
Respir Res; 2021 Jul; 22(1):204. PubMed ID: 34261470
[TBL] [Abstract][Full Text] [Related]
37. Systemic delivery of proresolving lipid mediators resolvin D2 and maresin 1 attenuates intimal hyperplasia in mice.
Akagi D; Chen M; Toy R; Chatterjee A; Conte MS
FASEB J; 2015 Jun; 29(6):2504-13. PubMed ID: 25777995
[TBL] [Abstract][Full Text] [Related]
38. Endogenous pro-resolving and anti-inflammatory lipid mediators: the new hope of atherosclerotic diseases.
Chen Y; Wang J; Nie R; Zhou S
Med Hypotheses; 2008 Aug; 71(2):237-40. PubMed ID: 18448265
[TBL] [Abstract][Full Text] [Related]
39. Specialized Pro-Resolving Lipid Mediators: Emerging Therapeutic Candidates for Multiple Sclerosis.
Zahoor I; Giri S
Clin Rev Allergy Immunol; 2021 Apr; 60(2):147-163. PubMed ID: 32495237
[TBL] [Abstract][Full Text] [Related]
40. Deletion of angiotensin-converting enzyme 2 promotes the development of atherosclerosis and arterial neointima formation.
Sahara M; Ikutomi M; Morita T; Minami Y; Nakajima T; Hirata Y; Nagai R; Sata M
Cardiovasc Res; 2014 Feb; 101(2):236-46. PubMed ID: 24193738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
